Key result
Statins, particularly pravastatin, show preliminary promise for preventing and treating preeclampsia.
Why the study?
Do statins prevent or improve the management of preeclampsia?
Do statins prevent or improve the management of preeclampsia?
Statins, particularly pravastatin, show preclinical promise for the prevention of preeclampsia, a condition sharing pathophysiologic mechanisms with cardiovascular disease.
Should not change preeclampsia management; leaves open hypothesis that pravastatin merits randomized trials.
Preeclampsia has been linked to high morbidity and mortality during pregnancy. However, no efficient pharmacological options for the prevention of this condition are currently available. Preeclampsia is thought to share several pathophysiologic mechanisms with cardiovascular disease, which has led to investigations for the potential role of statins (HMG CoA reductase inhibitors) in its prevention and early management. Pravastatin seems to have a safer pharmacokinetic profile compared to other statins, however, the existing preclinical evidence for its effectiveness in preeclampsia treatment has been mostly restricted to animal models. This review aims to summarize the current data and delineate the potential future role of statins in the prevention and management of preeclampsia.
No takes yet. Share an insight, caveat, or question.
Katsi et al. (2017) conducted a review in Preeclampsia. Statins (Pravastatin) was evaluated. Preliminary preclinical and case report data suggest that statins, particularly pravastatin, may be a promising therapeutic alternative for the prevention and treatment of preeclampsia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: